Januvia

Sitagliptin, the active ingredient in Januvia, is a DPP-4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving glycemic control. GNH USA supplies Januvia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Januvia is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers blood glucose levels and helps achieve target HbA1c. - Combination therapy with metformin: provides additional reduction in HbA1c when used together. - In patients inadequately controlled on diet and exercise alone: assists in reaching glycemic goals.

Common side effects are generally mild and transient.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Upper respiratory tract infection: mild cough or congestion. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain that may indicate pancreatic inflammation. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Joint pain: unexplained arthralgia that may require medical evaluation.

Before initiating therapy, several safety considerations should be reviewed. - Renal function monitoring: adjust use in patients with impaired kidney function. - Pancreatitis vigilance: educate patients to report persistent severe abdominal pain. - Hypersensitivity assessment: discontinue if signs of allergic reaction appear. - Elderly caution: start at lower doses and monitor for adverse events. - Store at room temperature: keep in the original pack, protect from moisture.

Sitagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase sitagliptin exposure. - Strong CYP3A4 inducers: may reduce sitagliptin effectiveness.

Moderate Interactions (Monitor Closely): - Insulin: combined use can increase risk of hypoglycemia. - Sulfonylureas: may potentiate hypoglycemic episodes. - Diuretics: can affect blood glucose control and require monitoring.